Pulse Explorer nav.journalClub Débats Tendances Chercheurs Revues

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Accueil Explorer nav.journalClub Tendances

⌘+K

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid | Synapse

May 10, 2026JDDG Journal der Deutschen Dermatologischen Gesellschaft0 citationsOpen Access

View Full Paper

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

NMNina Matthes JKJulian Kött FAFinn Abeck

Key Points

To assess the occurrence of psoriasis in a patient undergoing treatment with dupilumab for bullous pemphigoid.
Reported a clinical case of a patient with bullous pemphigoid and subsequent psoriasis after dupilumab therapy.
Detailed the patient's treatment history and clinical progression.
Psoriasis developed in the patient following dupilumab treatment for bullous pemphigoid, indicating a potential side effect of the drug.

Abstract

JK has received honoraria from Bristol-Myers Squibb, UCB, Sun Pharma, Sanofi, Novartis, Beiersdorf AG, doctorderma Online Hautarzt and Melatech, outside the submitted work. JK has received travel support from SUN Pharma and Pierre Fabre, outside the submitted work. FA and IHA received speaker fees from Sanofi, outside the submitted work. The other authors declare no conflict of interest.

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Matthes et al. (Fri,) studied this question.

synapsesocial.com/papers/6a002162c8f74e3340f9c4c2 https://doi.org/https://doi.org/10.1111/ddg.70397